Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Limiting Post-Smoking Cessation Weight Gain in Adult Smokers With Overweight/Obesity
NCT06173778Phase 2Recruiting
- Sponsor
- UTHealth Houston
- Start
- Apr 2024
- Primary completion
- May 2028
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial in obesity comparing semaglutide with placebo (2 arms). Primary endpoint: Change in Body Weight Percent at 28 weeks. Started Apr 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06173778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06173778.